<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669367</url>
  </required_header>
  <id_info>
    <org_study_id>PALABA 2017-004543-20</org_study_id>
    <nct_id>NCT03669367</nct_id>
  </id_info>
  <brief_title>EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)</brief_title>
  <acronym>PALABA</acronym>
  <official_title>EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to test the hypothesis that abatacept can reduce the
      progression of rheumatoid arthritis in ACPA+ or RF+ patients with palindromic rheumatism
      compared with patients treated with hydroxychloroquine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this trial is to test the hypothesis that abatacept can reduce the
      progression of rheumatoid arthritis in ACPA+ or RF+ patients with palindromic rheumatism
      compared with patients treated with hydroxychloroquine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>National multi-center study, open, controlled and randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main objective of this trial is to test abatacept efficacy</measure>
    <time_frame>At any time during the follow-up (up to 24 months)</time_frame>
    <description>number of participants developed persistent arthritis fulfilling criteria of Rheumatoid Arthritis according to EULAR/ACR 2010 classification criteria persistent arthritis (RA criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as asesed</measure>
    <time_frame>At any time during the follow-up (up to 24 months)</time_frame>
    <description>Number of participants with treatment-related adverse events as asesed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with titles positives on serum ACPA.(anti-CarP antibodies)</measure>
    <time_frame>At any time during the follow-up (up to 24 months)</time_frame>
    <description>number of participants with titles positives on serum ACPA.(anti-CarP antibodies)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Palindromic Rheumatism, Wrist</condition>
  <arm_group>
    <arm_group_label>abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>abatacept monotherapy (subcutaneous route).: 125 mg solution for injection in pre-filled syringe. In the first year (0-12 months) at a a dose of 125 mg per week (full dose) and in the second year (12-24 months) at a dose of 125 mg every other week (q2w) (optimized dose) injection) - 125 mg x week - subcutaneous use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydroxycloroquina</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxyclorquina (Coated tablet)- (5 mg/Kg/day) monotherapy for 2 years (0-48 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept Injection</intervention_name>
    <description>Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.</description>
    <arm_group_label>abatacept</arm_group_label>
    <other_name>ORENCIA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxycloroquina</intervention_name>
    <description>oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)</description>
    <arm_group_label>hydroxycloroquina</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with PR according to Guerne and Weissman modified criteria (18) and with:

          -  Disease evolution &gt; 3 months and &lt; 24 months.

          -  ACPA positivity proven by ELISA test or chemiluminescence (CCP2) and/or Rheumatoid
             factor positivity (ELISA, nephelometry or chemiluminescence).

          -  Greater than 18 years of age.

        Exclusion Criteria:

          -  Persistent arthritis: (involvement in one or more joints &gt; 1 week).

          -  Criteria of other rheumatic diseases (RA, SLE, etc.).

          -  Evidence of radiographic damage (join erosions).

          -  Absence of ACPA or RF.

          -  Contraindication or intolerance to study drugs (abatacept or hydroxychloroquine).

          -  Steroid treatment one month before study entry.

          -  Previous antitrheumatic therapy with synthetic DMARDS (methotrexate, leflunomide,
             sulfasalazine, cyclosporine, antimalarials.) or biological DMARDs.

          -  Pregnant women or who want to be pregnant during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Project manager Clinical Trial Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

